Skip to main content
Figure 2 | Arthritis Research & Therapy

Figure 2

From: Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement

Figure 2

Serum C-reactive protein (CRP; mg/l) and erythrocyte sedimentation rate (ESR) of individual patients for all dose groups from day 0, pre-infusion, until the end of the follow-up period for each dose group.

Back to article page